AAVantgarde Bio is a startup. 1 investor tracked.
Based in Italy, AAVantgarde Bio is a startup founded in 2018. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
AAVantgarde Bio is a clinical-stage biotechnology company focused on developing next-generation gene therapies for inherited retinal disorders (IRDs) using proprietary AAV vector platforms to deliver large genes.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.